Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Chase C. Leavitt currently holds 14,200 shares of Lineage Cell Therapeutics, Inc. (LCTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Chase C. Leavitt has been a net buyer of LCTX stock. They have purchased $43.8K and sold $0 worth of shares.
Chase C. Leavitt's most recent insider trade was on Feb 14, 2024, when they sold 14,200 shares at $0.00 per share.
Chase C. Leavitt serves as Executive at Lineage Cell Therapeutics, Inc. (LCTX). They have executed 12 insider transactions totaling $43.8K over their tenure at the company.
Chase C. Leavitt holds the position of Executive at Lineage Cell Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 7 years and currently hold a stake valued at $0.
Chase C. Leavitt has shown a buying trading pattern, with $43.8K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Chase C. Leavitt was on Jan 27, 2022, when they purchased $15.1K worth of ONCT shares. This transaction involved 8,500 shares at $1.78 per share.
Chase C. Leavitt currently owns 14,200 shares of Lineage Cell Therapeutics, Inc. (LCTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Chase C. Leavitt's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Chase C. Leavitt has 12 Form 4 filings on record as an insider at Lineage Cell Therapeutics, Inc..
Set alerts for Chase C. Leavitt and 40,000+ other insiders.